View from the Board: To IPO Now or Not?

4:00 PM - 4:55 PM, Tuesday, October 22, 2019 ・ 2nd Floor
With uncertain market conditions and concerns about realistic valuation expectations, innovative biotechs are trying to pinpoint the right time to go public. The right executive team and a clear, strategic roadmap have become more imperative as companies continually receive mixed signals from potential bookrunners and concerns are raised over IP in course of making a compelling case for going public and gaining access to capital markets. This panel will review how to structure those conversations and decisions around the current landscape and be as productive as possible toward timing the market accurately for a future IPO.
Speakers
photo
Former CEO
Ocera Therapeutics
photo
Chief Financial Officer
Cortexyme
photo
Partner
Morrison & Foerster LLP
photo
Managing Partner
Life Sciences Advisory
photo
Chief Financial Officer
Eidos Therapeutics